25.7 C
New York
Thursday, June 4, 2026

Tag: muscle

Young Explorers Invited to Discover Nature During Community BioBlitz at Muscle Shoals Reservation Trails

NORRIS, Tenn., June 2, 2026 /PRNewswire/ -- What glows under a black light? How many bird species can be spotted before lunch? What creatures...

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising...

Nxera’s Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea

Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)  announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Saint Herblain (France), August 18, 2025 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada1 and complements the adolescent label extension received in Europe in April 20252.

BestQool Announces Summer Promotion and Fall Refresh with New Logo and BQ60Pro Preview

Summer Appreciation Sales Offers 12% Off All Products NEW YORK, Aug. 15, 2025 /PRNewswire/ -- BestQool , a pioneer manufacturer of home-use red light therapy...

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3...

Dodge Showcases New 2026 Muscle Lineup at Woodward Cruise

AUBURN HILLS, Mich., Aug. 14, 2025 /PRNewswire/ -- ...

Sculpt By Science Unveils Exclusive Program to Empower CEOs and Entrepreneurs with Peak Performance

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Sculpt By Science introduces a groundbreaking health program designed to help CEOs, entrepreneurs, and business leaders optimize their well-being, leading to enhanced professional success.

AlphaCur Gains Momentum in 2025 as a Leading Formula for Neuropathy Nerve Health Support

AlphaCur Introduces Ingredient-First Nerve Health Formula as Interest in Neuropathy Support and Long-Term Wellness Grows in 2025
AlphaCur Introduces Ingredient-First Nerve Health Formula as Interest in Neuropathy Support and Long-Term Wellness Grows in 2025

High-tech Health for Students: Health-E Commerce® Highlights 10 Ways to Use Flexible Spending Accounts (FSA) and Health Savings Accounts (HSAs) for Digital Healthcare Products...

Tax-free FSA and HSA funds can be used to purchase health devices at FSA Store and HSA Store that treat conditions like acne, diabetes,...

Wong To Yick Wood Lock Medicated Balm Proudly Announces Cantopop Diva Joey Yung as Its First-Ever Brand Ambassador

"No.1 Meets No.1" – A Legendary Collaboration Redefining Excellence HONG KONG, Aug. 13, 2025 /PRNewswire/ -- Renowned Hong Kong heritage brand Wong To Yick Wood...

OIKOS® Launches First-of-Its-Kind Cultured Dairy Drink Featuring A Patented Blend of Nutrients Designed to Help Build & Retain Muscle Mass During Weight Loss

New OIKOS FUSION™ is the first product in the yogurt category with a proprietary combination of whey, leucine and vitamin D designed to support...

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model

-         The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMuscle